FDA rejects China-developed cancer drug Ivonescimab, setback for Beijing biotech
Published 1 d ago2 sourcesEvidence: Reported
The FDA declined Summit Therapeutics' application for ivonescimab, a cancer drug partnered with AstraZeneca. The rejection follows recent clinical collaboration agreements between the two firms, casting uncertainty over the drug's regulatory path and the partnership's near-term value.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Entities
Published 1 d ago2 sourcesEvidence: Reported
Published 17 h ago2 sourcesEvidence: Reported
Published 16 h ago2 sourcesEvidence: Reported
Published 11 h ago2 sourcesEvidence: Reported
Published 6 h ago1 sourceEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 1 d ago2 sourcesEvidence: Reported
Published 12 h ago1 sourceEvidence: Reported